Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation.

Thumbnail Image

Files

RT Failure v2 cp_DB+REFS.pdf (405.63 KB)

Embargo End Date

ICR Authors

Brand, Douglas
 Parker, Christopher

Authors

Brand, D
Parker, C

Document Type

Journal Article

Date

2018-04-01

Date Accepted

2017-12-18

Abstract

In men with prostate-specific antigen failure after radical radiotherapy, androgen deprivation therapy should be delayed until the site of recurrence is known to allow consideration of curative treatment options, to delay androgen deprivation therapy-related morbidity, and to enable earlier access to abiraterone and docetaxel.

Citation

European urology, 2018, 73 (4), pp. 521 - 523

DOI

10.1016/j.eururo.2017.12.021

URI

https://repository.icr.ac.uk/handle/internal/1021

Rights

https://www.rioxx.net/licenses/under-embargo-all-rights-reserved

Source Title

Publisher

ELSEVIER

ISSN

0302-2838

eISSN

1873-7560

Collections

Radiotherapy and Imaging

Research Team

Stereotactic and Precision Body Radiotherapy

Notes